Outlook Therapeutics

Outlook Therapeutics Announces NICE Recommendation of LYTENAV (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 new wet AMD patients each year in the UK who could benefit from treatment ISELIN,...
Outlook Therapeutics, Inc. 111 S. Wood Ave Unit,100 Iselin, NJ 08830

609.619.3990